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Abstract 
The Cooperative Health Research In South Tyrol (CHRIS) study is a population-based study with a longitudinal lookout 
to investigate the genetic and molecular basis of age-related common chronic conditions and their interaction with 
life style and environment in the general population. All adults of the middle and upper Vinschgau/Val Venosta are 
invited, while 10,000 participants are anticipated by mid-2017. Family participation is encouraged for complete pedi-
gree reconstruction and disease inheritance mapping. After a pilot study on the compliance with a paperless assess-
ment mode, computer-assisted interviews have been implemented to screen for conditions of the cardiovascular, 
endocrine, metabolic, genitourinary, nervous, behavioral, and cognitive system. Fat intake, cardiac health, and tremor 
are assessed instrumentally. Nutrient intake, physical activity, and life-course smoking are measured semi-quantita-
tively. Participants are phenotyped for 73 blood and urine parameters and 60 aliquots per participant are biobanked 
(cryo-preserved urine, DNA, and whole and fractionated blood). Through liquid-chromatography mass-spectrometry 
analysis, metabolite profiling of the mitochondrial function is assessed. Samples are genotyped on 1 million vari-
ants with the Illumina HumanOmniExpressExome array and the first data release including 4570 fully phenotyped 
and genotyped samples is now available for analysis. Participants’ follow-up is foreseen 6 years after the first visit. The 
target population is characterized by long-term social stability and homogeneous environment which should both 
favor the identification of enriched genetic variants. The CHRIS cohort is a valuable resource to assess the contribution 
of genomics, metabolomics, and environmental factors to human health and disease. It is awaited that this will result 
in the identification of novel molecular targets for disease prevention and treatment.
© 2015 Pattaro et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The Cooperative Health Research In South Tyrol 
(CHRIS) study is a population-based study with a lon-
gitudinal lookout established in 2011 to investigate the 
genetic basis of common chronic conditions associated 
with human ageing, and their interaction with life-style 
and environmental factors in the general population of 
South Tyrol. Located in the middle of the Alpine moun-
tainous region, the landscape is characterized by rural 
and small villages across many valleys. Agriculture 
and tourism are the major drivers of the gross domes-
tic product of the region, which is among the highest in 
Europe. In a context of a general worldwide life expec-
tancy increase, ageing is expected to be longest in such 
high income regions [1], which will also be characterized 
by a relevant demographic deficit [2], as documented 
in a recent report from the Autonomous Province of 
Bolzano/South Tyrol [3].
The CHRIS study is focused on cardiovascular, meta-
bolic, neurological, and psychiatric health. Cardiovascular 
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and metabolic diseases are major components of all non-
communicable diseases, whose burden will continue to 
increase over the next decades [1]. By 2030, more than 
40 % of the adult population could be affected by at least 
one cardiovascular condition [4]. Cardiovascular dis-
eases (CVD) will become the leading cause of death in 
65 + -year-old subjects and, at the current ageing rate, the 
cost to treat CVD will triplicate [5]. Similarly, prevalence 
of metabolic syndrome [6], diabetes, and particularly 
prediabetes [7], is rising. Among the neurological condi-
tions, the most prevalent disease in European regions of 
low child and adult mortality is migraine [8]. However, the 
increased burden of neurological diseases over the next 
fifteen years will be mainly due to the rising prevalence 
of dementias [9] and neuropathies. The CHRIS study 
pays particular attention to neurodegenerative move-
ment disorders, since they are generally under-recognized 
and under-treated, with a relevant impact on life quality 
and health economy. A South Tyrolean study representa-
tive of the general population [10] reported a prevalence 
of ~ 28 % in 50–89-year-old subjects, sharply increasing 
with age. Psychiatric health is also a major concern of 
European countries, with 14 % of the population suffering 
of anxiety disorders and nearly 7 % of major depression, 
with no particular differences by country [11].
Biomedical research is needed to identify factors that 
affect the ageing process, which may lead to preventive 
interventions for healthy ageing with reduction of health 
care related costs. For this reason, the CHRIS study was 
established as a collaboration between a research insti-
tute (the EURAC Center for Biomedicine) and the South 
Tyrolean Health System. Such a collaboration guarantees 
that the study operates by actively interacting with the 
local population, thus raising awareness towards a more 
conscious approach to health. The study is expected to 
foster a dynamic cycle among scientists, clinicians, and 
the whole population, which is to offer reciprocal feed-
back to ultimately improve individuals’ health.
Methods
Design, reference population, and recruitment
Study objectives
The CHRIS study has been established to accomplish the 
following objectives: (1) to identify biological mecha-
nisms underlying cardiovascular, metabolic, neurologi-
cal, and psychiatric health, and to understand how these 
mechanisms can be influenced by environmental expo-
sures; (2) to raise population’s awareness towards preven-
tion and health.
Study design and reference population
The CHRIS study invites all 18+-year-old inhabitants of 
the middle and upper Vinschgau/Val Venosta, a 70  km 
long valley in the autonomous province of Bolzano/
South Tyrol, Italy, at the border with Switzerland and 
Austria (mother tongue: German 97 %, Italian 3 %) [12]. 
The area comprises 13 municipalities, each one charac-
terized by a main center (inhabitants 270–4300), about 
30 sparse villages (inhabitants 50–800), and scattered 
mountain farms (Fig.  1). All settlements are located 
at an altitude of about 600–2000  m above sea level. At 
the time when the study started (24 Aug 2011), 28,497 
adult residents were registered in the electoral lists and 
formed our sampling basis. The aim is to recruit at least 
10,000 participants, roughly corresponding to 35  % of 
the whole adult population. To date, over 7000 adults 
already participated. Completion of the first phase of the 
study is expected by mid-2017.
Longitudinal perspective of the CHRIS study and follow‑up 
of the MICROS study
The study has a longitudinal design plan, with follow-up 
starting after 6 years from initial recruitment. In addition, 
the CHRIS study is being conducted in the same geo-
graphical area where the MICROS study was previously 
carried out in 2002/03 [12]. The MICROS study involved 
three of the municipalities included in the CHRIS study. 
All former living MICROS participants still resident in 
the area are now being invited into the CHRIS study. 
This group consists of 1259 subjects, for whom DNA and 
extensive clinical and biological phenotypes [13, 14] are 
available. With a 10+ year follow-up, those accepting to 
re-participate will thus constitute the first longitudinal 
nucleus within the CHRIS study.
Recruitment strategy
The recruitment center is located in the valleys’ refer-
ence hospital of Schlanders/Silandro, the central town 
of the valley. Population involvement proceeds gradually, 
expanding the study from one municipality to the contig-
uous one. This design allows a tailored communication 
strategy and monitoring of participation rate. In each 
municipality, the recruitment begins after an informa-
tive campaign (Fig.  2): (1) CHRIS study investigators 
share the study concept with local general practitioners 
(GPs); (2) GPs and CHRIS investigators meet the mayor 
and other relevant members of the municipality council; 
(3) the municipality council invites all leaders of local 
charities and voluntary organizations to a meeting with 
CHRIS investigators; (4) the study is first announced 
to the population through the local media and then the 
entire population is invited to one or more public meet-
ings where the study is officially introduced to the com-
munity. This last step guarantees direct interaction and 
discussion with the public. Afterwards, a first invitation 
letter is mailed to all 18+-year-old inhabitants, who are 
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identified through publicly available electoral lists. To 
favor the identification of genetic variants that might be 
enriched in single families, we encourage participation 
of the entire family. For this reason, the first invitation is 
mailed personally to each member of the same family at 
the same time. Up to two reminders are mailed to non-
responders to maximize participation into the study. All 
communication is bilingual (German/Italian) to equally 
involve both linguistic groups.
Enrollment and visit at the study center
The study is organized to enroll up to 10 participants/
day, who are required to have fasted overnight. After 
the informed consent procedure, participants undergo 
tremor assessment, blood drawing, urine collection, 
anthropometric measurements, a 20-min electrocar-
diographic (ECG) analysis, and blood pressure meas-
urement. Breakfast is offered after completion of all 
assessments to avoid any short-term effect of sugar, fat or 
caffeine consumption. Finally, participants respond to a 
computer assisted personal interview (CAPI) and a com-
puter aided self-interview (CASI).
Ethical and legal framework: a participant‑centric 
approach
The CHRIS study was approved by the Ethical Commit-
tee of the Healthcare System of the Autonomous Prov-
ince of Bolzano (Südtiroler Sanitätsbetrieb/Azienda 
Sanitaria dell’Alto Adige), protocol no. 21/2011 (19 Apr 
2011). In addition, the CHRIS study invested in creat-
ing a comprehensive ethical, legal, and social implication 
(ELSI) framework aimed at building and ensuring long 
lasting trust and participation [15]. The study is compli-
ant with current Italian and EU regulation and with the 
Helsinki Declaration. Privacy and security in data han-
dling and sharing are strictly enforced and a public access 
code regulates how data and samples can be used. Data 
and samples are only shared for specific projects and 
based on Material and/or Data Transfer Agreements [16].
Dynamic informed consent
Given that the CHRIS study is designed to be longitudi-
nal, with use of data and samples that will be extensive 
and prolonged in time, an interactive dynamic consent 
process for empowering participants’ autonomy and 
Fig. 1 Geography of the CHRIS study. Indicated are all municipalities involved in the study and the biobank location (Meran/Merano). Map source: 
Südtirol Marketing
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complying with current regulations was also imple-
mented. Dynamic consent includes two important parts: 
an ongoing information section and an interactive con-
sent webpage with dynamic options.
Information is provided in different formats to improve 
understanding through the use of diverse media that 
replace the information sheet. After booking the appoint-
ment, participants receive at home (by post or email) a 
detailed information brochure (http://www.chrisstudy.it), 
which includes a description of the study, images illus-
trating key concepts in lay language, and all ethical and 
legal issues relevant for the informed consent process. 
At the study center, the participant is invited to watch 
a 9 min information movie (available on the study web-
page) that systematically and fully explains the project. 
The movie shows the whole research workflow, outlines 
how data and samples are handled, what security meas-
ures are in place and what are the risks involved, and it 
describes the participant’s rights and information sources 
through images and small animations. After viewing, 
the participant can ask questions to the study assistants. 
While it was not meant to replace the oral communica-
tion between participant and study assistant, the intro-
duction of the movie had the effect of shortening the 
time needed for further explanations from about 20 min 
before its introduction to less than 5 min after its imple-
mentation. A yearly newsletter and updated information 
on the webpage complement the ongoing information for 
consent.
After the movie, electronic consent is filled in online 
directly on the personal interactive consent webpage. 
The type of consent asked is broad with regard to the 
aim of the study. At the same time, the consent is layered 
and provides dynamic options (changeable online over 
time) regarding data-sharing (international, public data 
repositories), return of secondary/unexpected results 
(outlining the right to know or the right not to know) and 
the permission to use samples and data in case of death. 
The data about the access levels granted by each partici-
pant goes directly into the database and is linked to their 
unique identification code. In this way data can be auto-
matically filtered for different purposes according to par-
ticipants’ choices. The dynamic tool can also be used for 
re-contact, collecting additional information and re-con-
sent, should this be necessary in the future. Participants 
can withdraw at any time by contacting the study center 
or online through username/password protected access. 
Three options are allowed: (a) complete withdrawal with 
data cancellation and sample destruction; (b) continued 
use of data but no re-contact; (c) data and sample usage 
limited to already running studies. A study on a sample 
of 500 consecutive participants is being carried out to 
assess participants’ feeling about the dynamic informed 
consent and satisfaction with the information provided.
Compensation and result notification
No financial compensation or travel cost reimbursement 
is offered to support participation. Before leaving the 
study center, participants receive a dismissal letter with 
the results of the anthropometric, impedance, and blood 
pressure measurements. One week after, participants 
receive a letter with the complete results of their clini-
cal assessments, including blood, urine, and 10-s ECG 
results validated by a clinician. Participants are invited to 
discuss the results with their GP. Laboratory life-threat-
ening findings are followed up through an emergency 
protocol which, via the study coordinator and the refer-
ence GP, guarantees that the participant is alerted in the 
shortest possible time. A senior medical doctor and the 
emergency department of Schlanders/Silandro hospi-
tal are covering necessary immediate interventions due 
to serious cardiac issues occurring during the ECG or 
Fig. 2 Communication workflow
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problems arising during blood drawing according to the 
study’s emergency protocols.
Secondary findings
Return of unexpected secondary or health threaten-
ing results is provided upon prior explicit participant’s 
request. In such a case, a multistage consent takes place 
so that the participant can effectively take a decision at 
the time when information is available, thus confirm-
ing if he/she truly wants such results back. In the event 
of genetic incidental findings, an agreement with the 
Health Care System genetic counseling unit ensures that 
participants are approached by a medical geneticist, who 
undertakes proper counseling before results are tested 
and confirmed.
Governance
CHRIS governance refers to an internal committee which 
monitors everyday issues (data and sample access, study 
management) and three oversight external bodies: the 
ethical board, the scientific board, and an evaluation 
committee that evaluates the project’s major changes 
and includes stakeholders from the local healthcare sys-
tem and study participants. Legal and ethical issues are 
described in the Ethical and Legal regulation published 
on the study website.
Data management
A dedicated and password protected network has been 
set up at the study center to secure data safety, integrity, 
and privacy. A local network connecting all electronic 
devices is linked to, and managed by, a central server, 
which is regularly monitored and backed up. Participants 
are assigned a barcode, which is especially useful to enter 
personal data correctly using the National Fiscal Code 
badge and to link all data and samples to the participant 
(unique barcode for all tubes, forms, and datasheets from 
the same participant). Web interfaces are driven by the 
open source software LimeSurvey (http://limesurvey.org) 
and connected using a PostgreSQL database.
Biospecimens
Collection
Blood (49 ml) and urine (30 ml) samples are collected at 
the study center for laboratory analysis and biobanking 
(Table  1). Biomarkers analysed include all main cardio-
vascular and metabolic risk factors (including fibrino-
gen, C-reactive protein, and homocysteine), antinuclear 
antibodies (marker of autoimmune disease and other 
metabolic dysfunction), and markers of iron metabo-
lism, coagulation, renal damage, thyroid, and liver func-
tion. Given the instability of some of the blood and 
urine parameters, including glucose and homocysteine, 
pre-analytical sample processing is performed immedi-
ately at the study center by trained nurses, to ensure reli-
ability and accuracy of all the measurements. Collected 
samples are shipped daily to the CHRIS laboratory at the 
hospital of Meran/Merano (Fig. 1) at room temperature 
or at 4  °C, as appropriate. During transportation, sam-
ple temperature is monitored and recorded by means of 
electronic thermometers placed inside the transportation 
bags. A software has been developed which uploads tem-
perature measurements automatically to a central server. 
An alert is sent out when a temperature curve falls out-
side the predefined control range.
Biobanking
About 28  ml of the collected blood and 3.3  ml of urine 
undergo cryopreservation (Table  1). Fractionated blood 
is aliquoted in small volumes in 2D-barcoded screw-cap 
vials (Thermo Scientific™ Nunc™ Bank-It™ Vial Systems) 
using a robotic liquid handler (Starlet, Hamilton Robot-
ics, CH-7402 Bonaduz, GR, Switzerland). Biospecimens 
are flash frozen via direct immersion in liquid nitro-
gen and stored at −80  °C. Whole blood and buffy coat 
aliquots are stored at −190  °C in nitrogen vapor. To 
maintain cell vitality in those aliquots, 10  % dimethyl 
sulfoxide is added (Sigma-Aldrich, D2650) and freez-
ing rate is controlled (CoolCell alcohol-free cell freez-
ing containers, BioCision, CA, USA) until the samples 
reach −80  °C before transfer to −190  °C storage. Three 
milliliters of EDTA whole blood are separated, frozen at 
−20 °C, and sent to a second biobank in Bozen/Bolzano 
for DNA extraction. This second biobank works also as a 
safety backup and receives 50 % of the samples for stor-
age. Genomic DNA extraction is performed using an 
automated platform for nucleic acid isolation (Chemagic 
Magnetic Separation Module I, PerkinElmer Chemagen 
Technologie GmbH, Germany) using a dedicated method 
based on magnetic beads (Chemagic DNA Blood Kit spe-
cial, PerkinElmer Chemagen Technologie GmbH, Ger-
many). DNA is automatically handled through a robotic 
liquid handler (Starlet, Hamilton Robotics, CH-7402 
Bonaduz, GR, Switzerland), eluted in 300  μl, quantified 
through absorbance (Epoch, Take3 Trio Micro-Volume 
Plate, BioTek Instruments, USA), and stored at –20 °C. A 
child aliquot (100 μl volume) is normalized at 100 ng/μl 
and stored at 4 °C.
Sample management, operation, and monitoring 
instruments are integrated in a Biobank Information 
Management System (BIMS). The system allows the 
monitoring of all standardized procedures and sam-
ple-handling operations. Access to the bioresource is 
regulated through an access regulation for internal and 
external use. The biobank has joined the Biobanking 
and Biomolecular Resources Research Infrastructure 
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(BBMRI) which provides protocols that guarantee top-
level biological and medical research by promoting pro-
cedure standardization and sample quality. In order to 
maximize transparency on the use of samples and data 
and for tracking the use of the bioresource, the CHRIS 
biobank was assigned a “Bioresource Research Impact 
Factor” (BRIF) code (http://www.p3g.org/brif-bioshare-
pilot-study): BRIF6107.
Genotyping
All CHRIS samples are genotyped on ~1 million sin-
gle nucleotide polymorphisms (SNPs) with the Illumina 
HumanOmniExpressExome Bead Chip, which includes 
~250,000 exonic variants. High coverage exome sequenc-
ing is foreseen for a large proportion of participants.
Assessing the compliance with a paperless study
CHRIS is predominantly a paperless study. Interviews 
and data-collection procedures are computer aided. At 
the planning stage, a feasibility study was performed to 
compare two modes of interview: a computer-assisted 
self-administered (CQ) versus a paper-based self-admin-
istered (PQ) survey questionnaire. A convenience sample 
of 66 adults was prospectively recruited from a general 
practice in the same rural area of the CHRIS study. Ques-
tionnaires and individual questions were selected to 
represent a broad range of both sensitive domains and 
measurement scales [17–19]. Two independent groups 
completed a test–retest assessment of the same ques-
tionnaire (PQ–PQ, n =  17; and CQ–CQ, n =  14). Two 
further independent groups completed the survey on 
Table 1 Biospecimens: collection tube and volume, material, parameters, and destination
CRP C-reactive protein, HDL high density lipoprotein, LDL low density lipoprotein, GGT gamma-glutamyl transferase, AST aspartate aminotransferase, GOT glutamic 
oxaloacetic transaminase, ALT alanine aminotransferase, GPT glutamate pyruvate transaminase, ALP alkaline phosphatase, anti-TPO AB anti-thyroid peroxidase 
antibodies, TSH thyroid-stimulating hormone reflex, FT4 free thyroxine, FT3 free triiodothyronine, HCT haematocrit, HGB haemoglobin, MCH mean cell haemoglobin, 
MCHC mean red blood cell haemoglobin concentration, MCV mean red blood cell volume, MPV mean platelet volume, RDW red blood cell distribution width, PLT 
platelet count, RBC red blood cell count, WBC white blood cell count, HbA1c glycated hemoglobin, INR international normalized ratio, PT prothrombin time, aPTT 
activated partial thromboplastin time, ACR albumin-to-creatinine ratio
Collection tube type Volume  
collected (ml)
Assay  
material
Purpose
Blood/Urine Analyses Biobank
Parameter No. 
of Ali‑
quots
Aliquot 
volume (µl)
Storage 
temp. (°C)
Serum gel + Clot Act. 
Venosafe VF108SAS
16 Serum Antinuclear antibodies; Albumin; CRP; 
Calcium; Chlorine; Potassium; Magne-
sium; Sodium; Phosphorous; Ferritin; 
Iron; Transferrin; Creatinine; Uric acid; 
Cholesterol; HDL; LDL; Triglycerides; 
Lipase; Direct and total bilirubin; GGT; 
AST; GOT; ALT; GPT; ALP; Cortisol; Glu-
cose; anti-TPO AB; TSH; FT4 and FT3 in 
case of abnormal TSH
15 220 –80
K2-EDTA Venosafe 
VF053SDK
15 EDTA plasma Monocytes; Basophils; Neutrophils; Lym-
phocytes; Eosinophils; HCT; HGB; Mean 
Red Blood Cell; MCH; MCHC; MCV; MPV; 
RDW; PLT; RBC; WBC; HbA1c
10 220 –80
EDTA buffy coat in 
RNA later
/ 4 490 –80
DNA / 2 Variable –20
Na3-Citrate Buffered 
Venosafe VF054SBCS07
14.5 Citrate plasma Antithrombin; Fibrinogen; INR; PT; aPTT 10 220 –80
Citrate buffy coat 
+DMSO
/ 1 900 –190
Citrate whole 
blood + DMSO
/ 3 1000 –190
Gel + Li.Heparin. Venosafe 
VF054SAHLAS
3.5 Heparin plasma Homocysteine / / /
Vacutest U218007/U14930 30 Urine pH; Glucose; Proteins; Haemoglobin; 
Ketone bodies; Bilirubin; Urobilinogen; 
Specific weight; Nitrites; Leukocytes-
esterase; Leukocytes; Erythrocytes; 
Epithelial cells; Bacteria; Creatinine; 
Albumin; ACR
15 220 –80
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both platforms according to a random sequence (cross-
over design; PQ-CQ, n = 16; CQ-PQ, n = 19). Question-
naire contents and structure were identical for the two 
platforms. The two platforms were compared according 
to measures of efficiency (e.g. completion time), con-
cordance, and general appraisal. In the cross-over group, 
concordance was excellent, with intraclass correlation 
coefficients ranging between 0.88 (Center for Epidemio-
logic Studies of the National Institute of Mental Health 
Depression scale [18], CES-D) and 0.99 (Pittsburgh Sleep 
Quality Index [20], PSQI, ‘hours of sleep’). Appraisal of 
either platform was either good or very good across mul-
tiple indicators, comprising quality of instructions, qual-
ity of presentation, usability, and general satisfaction 
with the tool. For example, at first administration ‘gen-
eral satisfaction’ had the highest score (82  % endorsed 
the top rank) on the computer platform, whilst ‘instruc-
tions’ had the lowest score on the same platform (68 %). 
However, appraisal ratings between platforms did not 
differ either at first administration (between independ-
ent groups of respondents, n = 66) or when completed at 
different times (cross-over design only, n = 35). Partici-
pants were slower on computer than on paper (Wilcoxon 
rank-sum test P value =  0.01), with median completion 
time of 12  min (interquartile range, IQR 11–17) and 
10  min (IQR 8–14), respectively. Participants filling out 
questionnaires on a computer had a fourfold data entry 
correction rate of those filling out the questionnaires on 
paper at first administration (negative binomial regres-
sion incidence rate: 4.2, 95  % confidence interval: 1.6–
10.8, P  value  <  0.01), after accounting for sex, age, and 
computer literacy. The large majority of participants of 
the cross-over study reported feeling less nervous when 
operating on computer than on paper (n = 32, 91 %). The 
majority of participants also reported that in the future 
they would favour CQ (n = 20, 57 %) versus PQ (n = 2, 
6 %), while 13 (37 %) had no preference. By acknowledg-
ing major advantages (e.g. accurate data immediately 
available) and minor limitations (e.g. longer completion 
time) of the computer-assisted questionnaires, further 
module improvements were implemented and larger 
fonts adopted to enhance module visualization. While 
participants are given the option to skip an entire ques-
tionnaire, should they feel uncomfortable with it, the 
hierarchical structure of the questions is controlled to 
preserve data consistency and limit missing values.
Screening interviews and clinical assessment
Questionnaires and interview structure
To guarantee the maximal comparability of CHRIS data 
to other large epidemiological studies, the PhenX toolkit 
was chosen for questionnaire and phenotype stand-
ardization [21]. The questionnaires were grouped in two 
parts: one filled in with the help of trained interview-
ers and one self-administered. The list of questionnaires 
is reported in Tables 2 and 3. A description of the main 
questionnaires is given in the clinical assessment section 
below, in the context of each specific discipline. Each 
interview includes the assessment of parental and grand-
parental information and number of first-degree rela-
tives. This information allows to reconstruct complete 
family trees up to five generations and opens the possi-
bility of future extensive pedigree reconstruction through 
interrogation of population records. Upon consent, the 
interview is recorded for later quality control.
Cardiovascular health
Screening questionnaires listed in Table  2 are used to 
capture information about different circulatory sys-
tem diseases (ICD X codes I00-I99). Diagnostic groups 
include ischemic heart diseases (including angina pecto-
ris, myocardial infarction), arrhythmic diseases (such as 
atrial fibrillation, sudden cardiac arrest), and other car-
dio- and cerebrovascular diseases including atheroscle-
rosis, hypertension, stroke, transient cerebral ischemic 
attacks, heart failure, pulmonary embolism, circulatory 
insufficiency, deep venous thrombosis, myocarditis, and 
cardiomyopathy. Information about the implantation of 
a pacemaker or an implantable cardioverter defibrillator 
and the presence of congenital heart malformations is 
also collected. Biochemical measures taken as potentially 
reflecting cardiovascular health include CRP, homocyst-
eine, antithrombin III antibodies, fibrinogen and blood 
clotting times (PT and aPTT) as well as blood counts 
and cell volumes, and main categories of lipids such 
as total cholesterol, HDL and LDL forms of cholesterol 
and triglycerides. Given the strong links with CVD and 
diabetes, renal function is assessed using the estimated 
glomerular filtration rate based on serum creatinine, and 
kidney damage is investigated using the urinary albumin-
to-creatinine ratio. Electrolyte homeostasis is assessed 
by serum magnesium, sodium, potassium, calcium, chlo-
ride, and phosphorous, some of which are strongly regu-
lated by the kidney and whose variations impact blood 
pressure regulation. History and presence of any kidney 
disease and doctor-diagnosed renal insufficiency are 
assessed through interview.
Metabolic and endocrine health
Body mass index (BMI), fat percentage, visceral fat, and 
subcutaneous fat are assessed through a body composi-
tion monitor (OMRON BF508). Participants are inter-
viewed for doctor-diagnosed diabetes, and fasting serum 
glucose and glycated hemoglobin (HbA1c) are meas-
ured. Since thyroid diseases are the third leading cause 
of hospitalization in South Tyrol, after hypertension 
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and cardiopathies, thyroid dysfunctions are assessed by 
means of detailed interviewer-administered question-
naire and by serum thyroid-stimulating hormone (TSH), 
supported by free thyroxine (FT4) and free triiodothy-
ronine (FT3) in case of abnormal TSH levels. Anti-TPO 
antibody measurements for thyroid autoimmune disor-
ders are measured as well.
Movement disorders
Movement disorders are assessed through screening 
questionnaires as detailed in Table 2. Among them, essen-
tial tremor (ET) is a major focus in the study as it is the 
commonest type of movement disorder in South Tyrolean 
adults [10]. It is related to other neurodegenerative con-
ditions, such as Parkinson’s disease. Clinical diagnosis of 
ET is usually performed by a neurologist, and its sever-
ity is assessed through standard rating scales such as the 
Fahn–Tolosa–Marin Tremor Rating Scale (TRS) [22] or 
through the quantification of tremor, for instance by the 
visual assessment of a spiral drawn on paper [23]. How-
ever, visual assessment is prone to subjectivity. Clinical 
assessment often lacks sensitivity to capture small, albeit 
relevant manifestations of tremor, making it difficult to 
assess the prodromal phase and progression of the dis-
ease. Validity and reliability of clinical and visual assess-
ment of tremor represent an actual challenge, limiting 
comparability both within and between studies. Digitized 
spiral analysis (DSA) is performed by drawing a spiral 
on a digital tablet connected to a computer. Each par-
ticipant draws six spirals on top of a guide, starting with 
Table 2 Clinical domains covered by the CHRIS study. Classes have been adapted by the International Statistical Classifi-
cation of Diseases and Related Health Problems 10th Revision (ICD-10). Relevant diagnostic codes are reported in paren-
thesis when matching the assessment modality
CAPI computer assisted personal interview, CASI computer assisted self interview, SQ screening questionnaire, PhenX based on PhenXToolkit standards (https://www.
phenxtoolkit.org/index.php)
Domain Field (ICD‑10 code) Mode of assessment (source), questionnaire; instrumental 
assessment
Diseases of the circulatory system Myocardial infarction; heart failure; cardiac 
arrhythmias (I20-25)
CAPI (PhenX); 10″ and 20′ ECG
Essential hypertension (I10) CAPI (PhenX); blood pressure measurement
Stroke (I64); including transient cerebral 
ischemic attack (G45)
CAPI Jackson Heart Study Screening Questionnaire [70]
Peripheral vascular disease (I73); pul-
monary embolism (I26); deep venous 
thrombosis
CAPI (PhenX)
Endocrine, nutritional and metabolic 
diseases
Diabetes mellitus (E10-14) CAPI KORA study [71]; serum glucose, plasma HbA1c
Disorders of thyroid gland (E00-07) CAPI; serum TSH, FT4, and FT3
Obesity and localized adiposity (E65-66) Body Mass Index, Bioimpedance
Diseases of the genitourinary system Renal insufficiency (N00-19) CAPI (PhenX); serum creatinine, urinary albumin-to-creatinine 
ratio
Diseases of the nervous system: extrapy-
ramidal and movement disorders
Parkinson’s disease (G20) CAPI [17]
Essential Tremor (G25.0) Digitalized spiralography
Restless Leg Syndrome (G25.8) CASI RLS Diagnosis and Rating Scale [72]
Diseases of the nervous system: other Migraine (G43) CASI Int’l Classif. Headache Disorders (ICHD-II)
Sleep disorders (sleep quality and behav-
ior) (G47); chronotype (G47.2)
CASI Pittsburgh Sleep Quality Index (PSQI) [20], R.E.M. Sleep 
Behavior Questionnaire (RBDQ) [73], Munich Chronotype Ques-
tionnaire (MCTQ) [28]
Pain (R52.0) including pain sensitivity CAPI Pain Sensitivity Questionnaire [27]; pressure and tension 
gauge algometer
Chronic pain CAPI Chronic pain questionnaire
Psychiatric disorders Anxiety (F40-41) CASI State-Trait Anxiety Inventory (STAI Y-2) [19]
Depression (F32-33) CASI Center for Epidemiologic Studies of the National Institute of 
Mental Health Depression scale (CES-D) [18]
Hypomania and mood (F30-39) Paper-based, self-administered; MINI International Neuropsychi-
atric Interview (M.I.N.I.) [32]; HCL-32 questionnaire for Energy, 
Activity and Mood [35]
Cognition and autonomic function Cognition impairment CAPI Mini-Mental State Examination (MMSE) [30]
Autonomic dysfunction CASI Composite Autonomic Symptom Score (COMPASS 31) [31]
Disturbances of smell (R43) Sniffin’ sticks [45]
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participant’s preferred hand and alternating between 
hands after each drawing. Data from the spiral record-
ings is extrapolated in three spatial dimensions (lateral, 
longitudinal and vertical) sampled at a rate of 130  Hz. 
After a semi-automated data cleaning procedure, several 
indicators are derived from the drawings in the spatial–
temporal dimensions, including speed, pressure, accel-
eration, tremor amplitude, tremor frequency, and tremor 
direction. The testing hypothesis is that a combination of 
multiple metrics may help classify subjects according to 
different patterns of their drawings, which may ultimately 
link to different types of tremor symptomatology. To the 
best of our knowledge, this is the largest population-based 
study to date that has been collecting digital recordings 
on a spiral. This peculiarity will allow deriving normative 
range values for these metrics at a population level and 
relating them to the population characteristics.
Chronic pain and pain sensitivity
Chronic pain affects a large proportion of the adult popu-
lation and represents a major impediment to the physi-
cal functioning of individuals [24]. An altered sensitivity 
to painful stimuli is also related to chronic pain, although 
the direction of this association is unclear [25, 26]. Both 
chronic pain and pain sensitivity are measured in the 
CHRIS study. Chronic pain is assessed through a module 
in the interview questionnaire, which specifically asks for 
the duration, intensity and frequency of any pain affect-
ing the musculoskeletal system, in particular back and 
joints. Pain sensitivity is measured both experimentally 
and through a questionnaire. The pressure pain thresh-
old (PPT) experimentally measures the level of pres-
sure (kg/cm2) at which pain is first perceived during a 
mechanical stimulus of increasing force. In our case, the 
pressure is applied vertically on the left index finger of 
the participant through a hand-held gauge algometer by 
a trained operator. The procedure is stopped as soon as 
the participant reports some level of pain. The pressure 
measured by the algometer at that point represents the 
individual’s PPT. The pain sensitivity questionnaire [27] 
(PSQ) is made of 14 items, relating to common daily life 
situations of mild or moderate painful experience. The 
respondent reports the imagined intensity of pain for 
each situation on a scale from 0 (no pain) to 10 (worst 
imaginable pain). The average of 14 items represents the 
PSQ-total score and measures the individual overall pain 
intensity rating. Two subscores are also derived, each by 
averaging a selection of 7 separate items representing 
mild painful situations (PSQ-minor) and moderate pain-
ful situations (PSQ-moderate), respectively.
Sleep and chronotype
Insomnia affects 7  % of the European population [11] 
and can be present as a primary condition or be related 
to medical conditions, such as endocrine, neurologic and 
psychiatric diseases. In particular, discerning whether 
poor sleep quality is prodromal to onset of mood disor-
ders or vice versa is an active area of research, and iden-
tifying common risk factors underlying low quality sleep 
and psychopathology may lead to new therapeutic targets 
for both disorders. In CHRIS, sleep quality is measured 
using the PSQI questionnaire [20]. The Munich Chrono-
type Questionnaire [28] was also implemented to gain a 
better understanding of the underlying complexity and 
individual differences of the biological clock, as shown 
in everyday behavior. Finally, the rapid eye movement 
(REM) sleep behavior disorder (RBD) is also assessed as 
it is often associated with other neurological conditions, 
such as Lewy body dementia, Parkinson’s disease or mul-
tiple system atrophy [29].
Table 3 Personal information, life-style, and exposures
Name of the questionnaire (acronym) Administration mode/method to collect  
the information (source, reference)
Semi‑quantitative 
outcome
Personal and family information  
(pedigree reconstruction)
Computer-assisted interviewer-administered questionnaire NO
Medication, last 7 days (medication bag) Electronic optical scan of medication boxes NO
Birth/early-life exposures Computer-assisted interviewer-administered questionnaire (KORA study) [71] NO
Food Frequency Questionnaire  
(including alcohol consumption)
Home-based, paper-based self-administered questionnaire (GA2LEN study) [56] Nutrient intake
Smoking habits Computer-assisted interviewer-administered questionnaire (EC Respiratory  
Health Survey II) [55]
Life-course smoking 
burden (pack-years)
Physical activity Computer-assisted self-administered questionnaire (Int’l Physical Activity Q)  
[54]
Metabolic Equivalent 
of Task (MET)
Environmental factors Postal address for geo-reference NO
Occupation Computer-assisted interviewer-administered questionnaire NO
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Cognitive function
Cognitive function is evaluated by the Mini-Mental State 
Examination (MMSE) [30], a 30-item screening ques-
tionnaire assessing different cognitive domains, such as 
memory, orientation to space and time, and language 
ability.
Autonomic function
The Composite Autonomic Symptom Score (COMPASS 
31) [31], a self-administered questionnaire on autonomic 
dysfunction, is used to assess the presence of autonomic 
symptoms. It consists of 31 questions about autonomic 
symptoms in 6 different domains: orthostatic intoler-
ance, vasomotor dysfunction, secretomotor dysfunction, 
gastrointestinal dysfunction, combining gastropare-
sis, diarrhea and constipation, bladder dysfunction and 
pupillomotor dysfunction.
Psychiatric health
Depression is assessed through the CES-D questionnaire 
[18] (Table 2). Anxiety is investigated by using the State-
Trait Anxiety Inventory (STAI Y2) [19], a 40-question 
questionnaire which allows to assess both state and trait 
anxiety. On a subsample of ~3000 participants, a deeper 
psychiatric assessment was introduced that encompasses 
major depression episodes as well as manic and hypo-
manic episodes [32]. These participants are also assessed 
for perceived stress [33], childhood trauma [34], mood 
[35], life-orientation [36], and family history of psychiat-
ric disorders. All interviews are self-administered.
Phenotyping of multi‑systemic functions
The screening described above spans over several 
domains. Some of these domains share common patho-
physiological mechanisms which can be assessed through 
additional instrumental or molecular phenotyping, as 
described below.
ECG and continuous non-invasive arterial pressure 
measurement A 10-s and a 20-min 12-lead ECG are 
recorded using a PC-ECG-System Custo 200 (Customed) 
workstation with a sampling rate of 1000 Hz. Participants 
are asked to remain in supine position and silent during 
the procedure. In addition to classical indicators of heart 
electrical conduction, such as PR, QRS and QT dura-
tion, the 20-min ECG allows the calculation of param-
eters that reflect the heart rate variability (HRV) [37], 
which is defined as the temporal variation between con-
secutive heart beats. HRV reflects the continuous inter-
action between neural modulatory mechanisms and the 
sinoatrial node rhythmicity. ECG measurement of HRV 
has already been described as an important tool to assess 
autonomic function [38] and to predict cardiovascular 
events in association with ageing [39], type 2 diabetes [40], 
metabolic syndrome [41] and other cardiovascular risk 
factors [42]. It has been recently demonstrated that the 
deceleration capacity [43], defined as the integral measure 
of all deceleration-related oscillations, strictly depends on 
the autonomous nervous system activity and is mainly an 
index of vagal activation. Furthermore, the periodic repo-
larization dynamic (PRD) is a parameter describing low 
frequency rhythmic modulation of repolarization that can 
be used to specifically assess the sympathetic effect on 
repolarization [43]. In a sample of 3000 participants, con-
tinuous non-invasive arterial blood pressure (BP) is meas-
ured and completely synchronized with the 20-min ECG. 
Such a simultaneous recording allows estimation of the 
post-extrasystolic BP potentiation (PESP), defined as the 
pulse wave augmentation in BP after a suitable ventricular 
premature complex [44]. PESP has been recently shown to 
strongly predict post infarction mortality. Its usefulness as 
a predictor of adverse cardiovascular outcome in the gen-
eral population deserves validation.
Olfaction assessment A smell test is assessed with 
Sniffin’ sticks (Burghardt Medizintechnik, Wedel, Ger-
many) [45]. A total of 16 odors related to common daily 
life experience have to be recognized from a list of four 
choices for each odor. Hyposmia, or olfactory dysfunc-
tion, is a prodromal symptom for Parkinson’s disease 
which often anticipates motor symptoms [46] and it has 
been shown to predict Alzheimer dementia as well [47]. 
Reduced smell ability was shown to discriminate between 
multiple system atrophy and pure autonomic failure [48], 
suggesting a possible role of its assessment in the differ-
ential diagnosis among dysautonomic syndromes. More-
over, a vast literature correlates smell dysfunction with 
schizophrenia [49].
Metabolomics of energy metabolism Energy metabolism 
and mitochondria in general are increasingly being linked 
to ageing [50, 51] and diseases that present themselves in 
mid to later stages of life [52, 53]. A systematic literature 
assessment of metabolites that capture mitochondrial 
function, with emphasis on metabolites that are directly or 
indirectly related to energy metabolism was undertaken. 
As a result, about 70 metabolites were identified with a 
broad spectrum of chemical properties including, but not 
limited to, amino acids, heterocyclic compounds, organic 
acids and mono-phosphate nucleotides. Plasma levels of 
the identified metabolites are being measured by liquid 
chromatography–tandem mass spectrometry (LC–MS). 
In addition to this hypothesis-driven investigation, untar-
geted metabolomics analysis in a subset of the participants 
will also be performed to identify novel metabolites.
Life‑style and environmental exposures
As detailed in Table  3, physical activity, food intake 
including alcohol consumption, smoking habits, and 
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early life exposures are collected by means of computer-
assisted self-and interviewer-administered question-
naires. Some of the questionnaires allow quantification 
of exposures as either quantitative variables or semi-
quantitative scores, which increases the statistical power 
to detect phenotype–environment associations or gene–
environment interactions compared with dichotomous 
exposures. This is the case for the International Physi-
cal Activity Questionnaires [54] (IPAQ), from which the 
Metabolic Equivalent of Task (MET) can be derived, 
the European Community Respiratory Health Survey 
(ECRHS) II smoking questionnaire from which life-
course smoking intake in terms of pack-years is derived 
[55], and the GA2LEN food frequency questionnaire 
(FFQ) from which an estimation of the nutrient intake 
[56] can be obtained. In the case of the GA2LEN FFQ, a 
paper-based format could not be avoided. The 20-page 
FFQ includes 229 items and requires ~25 min for com-
pletion. To limit the time spent at the study center, the 
questionnaire is mailed to the participants’ home at 
the time when the appointment is set up. At the study 
center, the questionnaire is visually inspected by a study 
assistant. In case of missing responses, the participant 
is asked to fill in the missing items. The questionnaire is 
then processed by an automatic optical mark recogni-
tion (OMR) system: all pages are processed with a high 
throughput scanner and data stored in our central Post-
greSQL database system. The deployed OMR system, 
SDAPS (http://sdaps.org), has been tailored to our study 
by in-house development. Correct assignment of col-
lected information to participant is guaranteed by use of 
individual participants’ barcode reported on each page. 
Correct sequence of data entered is guaranteed by an 
additional page specific barcode. Based on the first 1000 
participants, 100  % of the questionnaires was returned 
and 81 % had no missing items.
Results
In 2015, we froze the first data release which included 
4979 participants (male:female ratio  =  44  %:56  %) 
recruited until 15 July 2014. Participants’ characteristics 
by gender are given in Table 4. On average, subjects were 
46.2  years old (SD  =  16.4) with no difference between 
sexes. Ninety-four percent of subjects was born in South 
Tyrol. A diploma from a vocational school was the most 
common educational level attained, with females having 
a higher educational level than males. Eighteen percent 
males and 5.9 % females reported daily alcohol consump-
tion. Current smokers were 19.7 % of males and 16.7 % of 
females (P < 0.01). The majority of the sample was clas-
sified as doing high physical activity. Doctor-diagnosed 
hypertension was reported by 25.1  % males and 21.5  % 
females (P < 0.01) and 60.7 % males and 41.3 % females 
had a BMI > 25 (P < 0.01). When defining diabetes status 
based on serum glucose and glycated hemoglobin levels 
(see Table 4 footnote), 4.6 % males and 4.2 % females were 
classified as having diabetes, while a pre-diabetic condi-
tion was identified in 40.4  % males and 41.7  % females 
(P value 0.55). Finally, females had a slightly higher total 
cholesterol level than males (P < 0.01). Table 5 shows that 
the age and sex structure of the recruited sample is very 
similar to that of the general population of the region. An 
exception is the 75+-year-old group, which is underrep-
resented in the CHRIS study due to the logistic difficulty 
of very old people to travel to the study center. However, 
in general such similar distribution between sample and 
reference population suggests that the CHRIS study sam-
ple will be valuable also for epidemiological investiga-
tions. As an additional characterization of this sample, 
we observed 606 singleton and 4373 related subjects out 
of the 4979 participants. The related subjects could be 
connected through 186 pedigrees characterized by 3014 
founders, each one with 1–56 descendants (mean  6). 
Finally, 4570 samples have been fully genotyped and are 
available for genome-wide association studies. This data-
set will constitute the first nucleus for epidemiological 
investigations and genetic data analysis.
Discussion
Biomedical research is witnessing a paradigm shift from 
sickness to health, where the best way to prevent disease 
onset is to understand how the whole ageing process 
works in healthy individuals. For this purpose, longitu-
dinal studies based on the general population are of the 
greatest relevance. In addition to screening population 
health through extensive interviews and clinical exami-
nations, the CHRIS study has some distinctive features.
The target population in this restricted area of the Alps 
is characterized by a rather homogeneous life-style. Pre-
vious work from our group demonstrated that the popu-
lation in this area is stable, with low residential mobility 
across generations [12, 57, 58] and low inbreeding [59]. 
We previously observed a low to null impact of shared 
environmental components on biomarker heritability 
[13], which suggests homogeneous life-style and envi-
ronmental conditions. Such a homogeneity would con-
stitute an advantage in mapping causal genetic variants 
in this geographical area. The collection of non-genetic 
exposures such as diet, smoking, and physical activity 
will allow us to assess the extent of variability of life-style 
in this region and to test candidate gene-environment 
interactions for biomarker traits of interest and the most 
prevalent disease outcomes.
The reconstruction of familial information will allow 
the building of medium sized pedigrees which will facili-
tate the mapping of inherited variants. With the emphasis 
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currently being on low frequency genetic variants, iden-
tified through SNP arrays or next-generation sequenc-
ing technology, sampling a large set of the resident 
population in a small region is advantageous in terms of 
allowing reliable identification of alleles that may be rare 
elsewhere but possibly overrepresented in the region. 
Table 4 Characteristics of the 4979 participants included in the first CHRIS data release by gender
a Indicated is the actual number of non-missing values when <4979
b P values for difference between males and females were obtained from t and Fisher’s exact tests for continuous and categorical variables, respectively
c Based on the question: “During the last 12 months, on average how often have you drunk alcoholic drinks?”
d Based on the question: “Has a doctor ever said that you have high blood pressure or hypertension?”
e Prediabetes: serum glucose (mg/dl) 100–125 or glycated hemoglobin (HbA1c) (%) 5.7–6.4; diabetes: serum glucose (mg/dl) ≥ 126 or glycated hemoglobin (HbA1c) 
(%) ≥ 6.5
Participants’ characteristicsa Males N = 2212 Females N = 2767 P valueb
Age (years)—mean (SD) 46.5 (16.4) 45.9 (16.3) 0.22
Self-reported origin—n (%)
 South Tyrol 2087 (94.4) 2591 (93.6) 0.40
 European 122 (5.5) 174 (6.3)
 Non-European 3 (0.1) 2 (0.1)
Education, n = 4976—n (%)
 No formal education or degree 5 (0.2) 7 (0.3) <0.01
 Primary school 223 (10.1) 379 (13.7)
 Lower secondary school 311 (14.1) 401 (14.5)
 Vocational school 1070 (48.4) 985 (35.6)
 Upper secondary school 427 (19.3) 703 (25.4)
 University 176 (7.9) 289 (10.5)
Alcohol consumption frequencyc, n = 4974—n (%)
 Never to seldom 489 (22.1) 1389 (50.3) <0.01
 ≤1 day/week 684 (30.9) 897 (32.5)
 ≥2 days/week 630 (28.5) 313 (11.3)
 Daily 408 (18.5) 164 (5.9)
Smoking habits, n = 4977—n (%)
 Never smoker 1024 (46.3) 1550 (56.1) <0.01
 Past smoker 752 (34.0) 753 (27.2)
 Current smoker 436 (19.7) 462 (16.7)
Physical activity, n = 4683—n (%)
 Low 502 (24.2) 626 (24.0) <0.01
 Moderate 507 (24.5) 853 (32.7)
 High 1063 (51.3) 1132 (43.4)
Blood pressure (BP), n = 4971—mean (SD)
 Systolic BP (mm/Hg) 124.5 (14.5) 115.3 (17.1) <0.01
 Diastolic BP (mm/Hg) 79.3 (9.0) 76.6 (9.5) <0.01
Elevated blood pressured, n = 4953—n (%)
 No 1647 (74.9) 2163 (78.5) <0.01
 Yes 551 (25.1) 592 (21.5)
Body-Mass-Index kg/m2, n = 4916—n (%)
 <25 856 (39.3) 1607 (58.7) <0.01
 25–30 972 (44.6) 701 (25.6)
 ≥30 350 (16.1) 430 (15.7)
Diabetes statuse, n = 4967—n (%)
 No 1215 (55.0) 1491 (54.0) 0.55
 Prediabetes 891 (40.4) 1151 (41.7)
 Diabetes 102 (4.6) 117 (4.2)
 Serum total cholesterol (mg/dl)—mean (SD) 207.8 (41.7) 213.0 (40.3) <0.01
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While the level of enrichment of low frequency variants 
may not be expected to be as large as that of populations 
undergoing strong genetic isolation [60], it is likely that 
the CHRIS population sample could show more enrich-
ment than general population studies. The absence of 
founder effects may keep the effective population size 
of the study large [61] which, paired with environmen-
tal homogeneity, should translate into higher power of 
detecting genetic associations. The study is planned to 
recruit about 10,000 subjects, corresponding to roughly 
35 % of the entire population in the region. Despite the 
typical issues of Alpine valleys in respect to traveling 
time and conditions necessary to reach the study center 
especially from the more remote villages, we believe this 
rate is reasonably achievable.
Currently, the genetic epidemiology community is fac-
ing the issue of data sharing and harmonization. Data 
harmonization, pooling, and sharing are beneficial to 
scientific research provided that data security and pri-
vacy are guaranteed [62]. This aspect may be particularly 
relevant now that rare genetic variants are being con-
sidered more frequently, given their functional nature, 
and data-sharing might become the only way to increase 
study power. In fact, population-based research is under 
two opposite ethical pressures: on the one hand it is 
imperative to protect data privacy and security, on the 
other hand, an ethically responsible research should aim 
at maximizing the use of stored data and samples, so as 
to guarantee the maximal benefit to the community [16]. 
For this reason, with the aim of maximizing the scien-
tific harvest of the CHRIS study, collaborations that are 
instrumental to data harmonization within the Italian 
Hub of Population Biobanks [63] and the Biobank Stand-
ardisation and Harmonisation for Research Excellence in 
the European Union (BioSHaRE) initiative [62, 64] were 
set up. In particular, the BioSHaRE project framework 
allows sharing data analysis results without real sharing 
of the personal-level data, thanks to the new DataSH-
IELD technology [65].
A relative advantage of a population-based study of 
limited sample size conducted in a small region might 
be the quicker turn-around to establish focused research 
studies nested into the CHRIS study. The strict collabo-
ration with GPs and hospital doctors from the valley’s 
central hospital made it easier to build up a trust relation-
ship, so that re-invitation of participants for additional 
deep phenotyping has been proven to be a realistic tar-
get. Along the same line, from a biobanking perspective, 
such a manageable sample size opens up the possibility 
of creating a very thick layer of phenotypes from the col-
lected biomaterial. Projects are already ongoing that will 
establish a broad range of molecular phenotypes covering 
a wide spectrum of metabolites through LC–MS analysis, 
effectively extending our previous work [14, 66]. In this 
context, small studies are particularly suitable for gene 
discovery, given that essential metabolites are generally 
regulated by a very few genes with large effects [14, 66].
Europe is under an unprecedented ageing phase, which 
brings the need of a global initiative to prevent morbidi-
ties typical of the elderly [67]. A global approach includes 
health promotion among the most important policy 
stakeholders. By enrolling a large portion of the total 
population and directly involving all GPs and munici-
pality councils of the region, the CHRIS study acts as an 
important player in raising the attention towards health-
ier ageing. In addition to the unavoidable sensitization 
which passes through invitation and participation in our 
screening program, participants are explicitly recom-
mended to visit their reference GPs for interpretation of 
the clinical examination results. Informative events are 
planned in collaboration with local charities promoting 
knowledge and prevention of the diseases, so that CHRIS 
researchers are involved in health-promoting events 
which go beyond the communication about the study. 
Table 5 Age and sex distribution of CHRIS participants compared to the general population of Vinschgau/Val Venosta
a Data are referred to the same municipalities included in the study. Data were obtained by the Statistical Institute of the Autonomous Province of South Tyrol 
(ASTAT): http://www.provincia.bz.it/astat/it/service/dati-online.asp
Age First CHRIS data release Resident population 2012a
Males Females Total Males Females Overall
n (%) n (%) n (%) n (%) n (%) n (%)
18–29 442 (20.0) 576 (20.8) 1018 (20.5) 2834 (19.9) 2661 (18.7) 5495 (19.3)
30–44 583 (26.4) 739 (26.7) 1322 (26.6) 3864 (27.1) 3659 (25.7) 7523 (26.4)
45–59 708 (32.0) 879 (31.8) 1587 (31.9) 4001 (28.0) 3739 (26.3) 7740 (27.2)
60–74 370 (16.7) 441 (15.9) 811 (16.3) 2340 (16.4) 2358 (16.6) 4698 (16.5)
75+ 109 (4.9) 132 (4.8) 241 (4.8) 1238 (8.7) 1803 (12.7) 3041 (10.7)
Overall 2212 (100) 2767 (100) 4979 (100) 14,277 (100) 14,220 (100) 28,497 (100)
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Current efforts are being dedicated to create groups of 
local promoters of healthy ageing studies, which may 
help in sensitizing the population towards participation 
and may also have a role in highlighting special popula-
tion needs so as to orient research towards applied solu-
tions that are closer to the population needs. To propose 
a concept where health can be shaped together by people 
and scientists, a general initiative was started, where the 
representatives of the largest associations of the valley 
together with GPs and local schools are being involved. 
This group has the purpose to promote health-related 
initiatives in the valley, increase the level of attention 
towards health-related topics, and hopefully create a phi-
lanthropy culture which can not only support, but foster 
scientific biomedical research in the region.
In a time when very large biobanks have been estab-
lished [68], strict scientist-population turnaround may 
be an advantage for mid-sized studies in order to achieve 
phenotype coverage of the target population, preci-
sion and homogeneity of the phenotype measurements, 
and support from the study participants themselves to 
expand the study into novel areas of biomedicine. On 
these premises, the CHRIS study will serve as foundation 
for a larger biomedical research effort aimed at uncover-
ing genetics and molecular markers that can be predic-
tive of individuals’ ageing trajectories as well as serve as 
potential therapeutic targets in disease progression con-
trol [69].
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